The [PEARL] Study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women

Trial Profile

The [PEARL] Study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PEARL
  • Most Recent Events

    • 01 Sep 2017 Planned number of patients changed from 132 to 46.
    • 01 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Jan 2019.
    • 01 Sep 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top